Navigation Links
Crux Biomedical Named One of Top 50 Companies to Watch
Date:7/12/2010

MENLO PARK, Calif., July 12 /PRNewswire/ -- Crux Biomedical® was named one of "50 Companies to Watch" in an annual survey of medical device and diagnostic companies. The survey, conducted by Medical Device and Diagnostics Industry (MD+DI), was published in its June 2010 issue. The purpose of the survey was to identify firms that have either achieved success or have the potential to revolutionize medical practice with their respective products.

Crux Biomedical, founded in 2004 by Dr. Thomas Fogarty, has targeted the development of an advanced implantable vena cava filter (VCF) to prevent the occurrence of a potentially fatal  pulmonary embolism (PE).  Each year in the United States, approximately 600,000 patients develop a PE and an estimated 200,000 deaths occur. This is more than the combined deaths associated with breast cancer, highway fatalities and AIDS. The U.S. market for VCFs  is valued at $300MM and growing between 8-10% annually.

Although routinely used in the United States, currently cleared vena cava filters are associated with a variety of complications including filter tilt and retrieval difficulty. The  Crux VCF is designed to address limitations of currently available VCFs.  "The Crux VCF is designed to self-center in the vena cava and has the advantage of retrievability from either the femoral or jugular approach," stated Eric Johnson, V.P., R&D of Crux Biomedical.

Crux Biomedical is currently enrolling patients in its pivotal IDE study in the United States and several international locations. It expects to complete enrollment by the end of 2010. "We are
'/>"/>

SOURCE Crux Biomedical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Crux Biomedical Enrolls First Patient in Its Retrieve 2 U.S. Pivotal Trial
2. Drexel Biomedical Researchers Develop Device to Predict Diabetic Wound Healing
3. West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund
4. Binder Biomedical, Inc. Announces the Release of the X-GRAFT(TM) Interspinous Device, as Part of Their QUANTUM(TM) Line of Spinal Allograft Devices, Manufactured at the University of Miami Tissue Bank
5. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
6. Biomedical Advanced Research and Development Authority (BARDA) Project for Radiation Exposure Research Awarded to SRI International
7. Volcano Corporation Completes Acquisition of Lumen Biomedicals Xtract(TM) Thrombus Aspiration Catheter
8. Nominations Open for the 2010 Dr. Paul Janssen Award for Biomedical Research
9. Subsidiary of Nova Biomedical Completes Acquisition of Assets of CCS Medicals Subsidiary, Sanvita, Inc.
10. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
11. NIH Funds New Wellstone Research Center for Muscular Dystrophy at Boston Biomedical Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 2015  Genoa has acquired West Bend Assisted Living ... pharmacy location with a proven track record for excellent ... settings, and those involved in their care. Both companies ... delivering true value to their customers. ... of pharmacy services dedicated to the behavioral health community ...
(Date:7/1/2015)... July 1, 2015 Egalet Corporation (Nasdaq: ... pharmaceutical company focused on developing, manufacturing and marketing ... Radie , president and chief executive officer, is ... He will provide an update on Egalet,s marketed ... Nasal Spray, approved product OXAYDO ™ (oxycodone ...
(Date:7/1/2015)... FRANCISCO , July 1, 2015 ... market) is expected to reach USD 49,119.2 million by ... Research, Inc. Monitoring services is expected to remain the ... of USD 1,227.5 million in 2012, and an estimated ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , Browse ...
Breaking Medicine Technology:Genoa, a QoL Healthcare Company Acquires West Bend Assisted Living Pharmacy 2Egalet to Present at Upcoming Conferences This Summer 2Egalet to Present at Upcoming Conferences This Summer 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 2mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 3mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 4mHealth Market Worth $ 49,119.2 Million By 2020: Grand View Research, Inc. 5
... announced today that it has licensed technology from Yale University ... in the January issue of the journal Cell Cycle ... associated with breast cancer risk, such mutations in BRCA1 ... The research identified microRNA disrupting variants in and around ...
... N.J., Feb. 24, 2011 University Radiology Group, ... teleradiology services, is working with MedInformatix Inc. to ... to achieve Stage 1 meaningful use ... Reinvestment Act (ARRA) for Health Information Technology. ...
Cached Medicine Technology:Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University 2University Radiology Group Works With MedInformatix to Meet Stage 1 Meaningful Use Qualifications 2University Radiology Group Works With MedInformatix to Meet Stage 1 Meaningful Use Qualifications 3
(Date:7/1/2015)... Tokyo, Japan (PRWEB) , ... July 01, 2015 ... ... August 2015 of a new extraction plant for Linablue®, Spirulina-derived natural blue food ... Earthrise Nutritionals, LLC, the DIC Group’s U.S. Spirulina* production base, began in May ...
(Date:7/1/2015)... ... July 01, 2015 , ... Summer recess has a ... to fix noses and chins with plastic surgery when they’re looking for a boost ... than 236,000 cosmetic procedures were performed on patients ages 19 and younger in 2012, ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... As if ... symptom found in a significant number of women: leg pain. Northeast Houston Vein Center ... Leg pain, a symptom of venous reflux disease, is underdiagnosed and often overlooked. Many ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Scoliosis is a disorder in which the ... Scoliosis Foundation, it affects 2 to 3 percent of the population, or an estimated 6 ... often develops in children between the ages of 10 and 15. Most types of scoliosis ...
(Date:7/1/2015)... ... July 01, 2015 , ... Bunion Bootie, the ... Customers purchasing two or more Bunion Booties directly from their website, http://www.BunionBootie.com ... temporarily corrects misaligned toes and its ultra thin properties allow for protection against ...
Breaking Medicine News(10 mins):Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 2Health News:DIC Strengthens Its Position as the Global Leader for Natural Blue Food Coloring 3Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 2Health News:Top Manhattan Facial Plastic Surgeon Dr. Sam Rizk Comments on Teen Surgery Trends 3Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 2Health News:Northeast Houston Vein Center Offers Tips for Women with Leg Pain 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 2Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 3Health News:Scoliosis: A Guide for Parents from Orthopedic Surgeon Dr. Fabien Bitan 4Health News:Bunion Bootie, the #1 Non-Surgical Treatment for Bunion Pain, Announces Their Big Summer Sale 2
... SCHAUMBURG, Ill. , Jan. 20 The American ... joined a coalition of other animal health and welfare groups to ... following the January 12 earthquake that devastated the country. ... was developed by the International Fund for Animal Welfare (IFAW) and ...
... found that acyclovir, a drug widely used as a safe ... virus-2 (HSV-2), which is the most common cause of genital ... taken by people infected with both HIV and HSV-2. ... New England Journal of Medicine online today, and will ...
... NJ A new brain-based computational model is ... medicationsused to treat motor symptoms caused by the ... reported in a forthcoming article in the ... a new computational model, developed by Drs. Ahmed ...
... injections could boost treatment, experts say, but safety concerns ... new drugs -- both oral, rather than injected -- may ... all being published early online Jan. 20 in the ... drugs -- fingolimod and cladribine -- reduce relapse rates in ...
... , Jan. 20 Family Research Council ( ... the following statement regarding the Massachusetts Senate election results: ... to be in the left-hand column into eternity, the results of ... visit to the Bay State made it clear that ...
... recent years, there has been a large increase in the ... approximately 51% of non-pregnant women ages 20 to 39 being ... in the journal Nursing for Women,s Health finds ... birth defects, as well as a greater risk of childhood ...
Cached Medicine News:Health News:U.S. Veterinarians Join Coalition to Help Haiti 2Health News:U.S. Veterinarians Join Coalition to Help Haiti 3Health News:Herpes medication does not reduce risk of HIV transmission, UW-led international study finds 2Health News:Herpes medication does not reduce risk of HIV transmission, UW-led international study finds 3Health News:Herpes medication does not reduce risk of HIV transmission, UW-led international study finds 4Health News:A novel computational model -- how Parkinson's medications affect learning and attention 2Health News:First Oral Medications For MS Show Promise 2Health News:First Oral Medications For MS Show Promise 3Health News:FRC: Mass Election Results a Near Revolutionary Rejection of President Obama's Leftist Agenda 2Health News:Pregnant women who are overweight put their infants at risk 2
Porous foundation 440 series....
Exactech's AcuMatch C-Series (cemented femoral stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The Biopro optima stem is manufactured from cobalt chrome and is available in a Non-Porous coat option....
The cemented hip joint prosthesis system....
Medicine Products: